Physician profile
Michelle E Mcateer
NPI 1033905955
$575.26
in general payments reported to CMS, 2019-2025
10 companies · $575 in 2025
The $575 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $505.27 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $108.26 | 2025 | Wegovy, Ozempic |
| Astellas Pharma US INC | $106.60 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $102.22 | 2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $87.81 | 2025 | |
| Lilly USA, LLC | $41.25 | 2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $31.70 | 2025 | The Cologuard Plus Collection Kit |
| Recordati_rare_diseases_inc. | $30.07 | 2025 | Isturisa |
| Shield Therapeutics INC | $28.36 | 2025 | |
| Glaxosmithkline, LLC. | $19.80 | 2025 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $19.19 | 2025 | Recorlev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Mcateer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.